The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice
| العنوان: | The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice |
|---|---|
| المؤلفون: | Pedro Marcos Gomes Soares, Silvânia Maria Mendes Vasconcelos, Emmanuel P. Souza, G. A. C. Brito, Ana Luiza Viana Pequeno, Conceição da Silva Martins, Daniely Viana da Silva Costa, Ingridy da Silva Medeiros, Dainesy Santos Martins, Angeline M. H. P. Silva, Roberto C. P. Lima-Júnior, Caren Nádia Soares de Sousa, Deiziane Viana da Silva Costa |
| المصدر: | Pharmaceuticals, Vol 13, Iss 361, p 361 (2020) Pharmaceuticals Volume 13 Issue 11 Repositório Institucional da Universidade Federal do Ceará (UFC) Universidade Federal do Ceará (UFC) instacron:UFC |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Pharmaceutical Science, lcsh:Medicine, lcsh:RS1-441, Antioxidantes, Inflammation, Irinotecan, Gastroenterology, Antioxidants, Article, Irinotecano, lcsh:Pharmacy and materia medica, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Drug Discovery, medicine, Mucositis, irinotecan, biology, business.industry, Intestinal villus, lcsh:R, Glutathione, medicine.disease, Inflamação, Diarrhea, 030104 developmental biology, medicine.anatomical_structure, antioxidants, chemistry, inflammation, 030220 oncology & carcinogenesis, Myeloperoxidase, biology.protein, Duodenum, Molecular Medicine, gut, lipids (amino acids, peptides, and proteins), medicine.symptom, business, medicine.drug |
| الوصف: | Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays. In this study, we investigated whether alpha-lipoic acid (&alpha LA) could improve irinotecan-mediated intestinal inflammation, diarrhea and dysmotility. Intestinal mucositis was induced by irinotecan injection (75 mg/kg, i.p., for 4 days) in Swiss mice. &alpha LA (50, 100 or 200 mg/kg, gavage) was administered daily 1 h before the injection of irinotecan. Duodenum tissues were obtained for inflammation and proliferation analysis. The outcomes: diarrhea, intestinal dysmotility, weight body loss and survival were evaluated. Compared with the control condition, irinotecan diminished (p < 0.05) intestinal villus height, caused a loss of crypt integrity and intense inflammatory cell infiltration, increased myeloperoxidase (MPO), IL-6 and IL-1&beta levels and decreased reduced glutathione (GSH) levels in duodenum segments and increased gastric retention and decreased liquid retention in the medial intestinal segment, resulting in increased intestinal transit, severe diarrhea and reduced survival (approximately 72%). Furthermore, &alpha LA (200 mg/kg) pretreatment ameliorated (p < 0.05) these irinotecan-induced effects. Our findings show that &alpha LA reduced irinotecan-induced inflammation, intestinal dysmotility and diarrhea, resulting in improved survival. &alpha LA may be a useful therapeutic agent for the treatment of gut dysmotility in patients with intestinal mucositis associated with irinotecan treatment. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1424-8247 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9652455f7e5fe78d34c8cda6deb34b1Test https://www.mdpi.com/1424-8247/13/11/361Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e9652455f7e5fe78d34c8cda6deb34b1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14248247 |
|---|